ARCH Venture Partners XII acquires over 5M shares in SPTX IPO aftermath; major institutional vote of confidence at listing price
ARCH Venture Partners XII, a 10% beneficial owner of Seaport Therapeutics, executed a substantial open-market purchase of over 5 million shares on the stock's second trading day—a significant institutional commitment that coincides with the company's recent IPO. The timing is notable: the fund is buying at the listing price level after having already participated in the private placement rounds that likely seeded its beneficial ownership stake. This isn't insider knowledge driving the trade, but rather portfolio capital allocation—ARCH is doubling down on its conviction in the biotech therapeutics opportunity the company represents. The purchase reflects institutional confidence that the newly public shares offer fair value at current levels, which could signal that the market's initial pricing is reasonable from the fund's perspective.